Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 501Carcinoma, Renal Cell 164Urinary Bladder Neoplasms 135Carcinoma, Transitional Cell 71Carcinoma, Non-Small-Cell Lung 57Kidney Neoplasms 55Melanoma 53Breast Neoplasms 51Ovarian Neoplasms 43Neoplasms 41Neoplasm Metastasis 40Colorectal Neoplasms 38Lung Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Sarcoma 24Endometrial Neoplasms 24Triple Negative Breast Neoplasms 21Pancreatic Neoplasms 19Esophageal Neoplasms 18Carcinoma, Hepatocellular 17Wilms Tumor 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Urologic Neoplasms 14Colonic Neoplasms 14Urethral Neoplasms 13Ureteral Neoplasms 13

Interventions

pembrolizumab 1liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Hereditary Sensory and Autonomic Neuropathies × Genitourinary × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Nimbus Therapeutics

Phase 1/2 Active not recruiting
106 enrolled
GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡